Pedro Magalhães Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Magalhães Ferreira has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Cláudia Freitas
CHUSJ—Centro Hospitalar e Universitário de São João, 4200-319 Porto, Portugal
4 shared publications - Helder Novais Bastos
Centro Hospitalar Universitario de Sao Joao
4 shared publications Francisco Machado
Department of Pulmonology, Centro Hospitalar Universitário de São João, Alameda Professor Hernani Monteiro, Porto, Portugal
3 shared publicationsNatália Melo
Department of Pulmonology, Centro Hospitalar Universitário de São João, Alameda Professor Hernani Monteiro, Porto, Portugal
3 shared publications- 2 Adriana Magalhães1
Centro Hospitalar Universitario de Sao Joao
2 shared publications - 2 David Araújo1
Departamento de Pneumologia, Centro Hospitalar Universitário de São João, Porto, Portugal. 2. Faculdade de Medicina, Universidade do Porto, Porto, Portugal
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Taylor & Francis in Pulmonology
- Vol. 32 (1)
Serum Index for Malignant Pleural Effusion (SIMPLE): A non-invasive, blood-based prognostic score for patients with newly diagnosed and relapsing MPE
The development of malignant pleural effusion (MPE) is often viewed by clinicians and patients alike as a significant hallmark of overall poor prognosis in the follow-up of different primary cancer...
- 21 July 2026
- Published by Taylor & Francis in Pulmonology
- Vol. 32 (1)
Open AccessSerum Index for Malignant Pleural Effusion (SIMPLE): A non-invasive, blood-based prognostic score for patients with newly diagnosed and relapsing MPE
The development of malignant pleural effusion (MPE) is often viewed by clinicians and patients alike as a significant hallmark of overall poor prognosis in the follow-up of different primary cancer...
- Open Access
- 19 June 2026
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 33 (3)
Definitive Pleural Interventions and Survival in Malignant Pleural Effusion
Background: Malignant pleural effusions (MPE) are associated with poor prognosis. Guidelines prioritize palliation of symptoms, recommending thoracentesis, pleurodesis or indwelling pleural catheters (IPC) based on predicted survival and patient preference. However, prognosis estimation in MPE is often inaccurate, and recent studies suggest MPE is not a bystander in the broader context of oncologic disease. Methods: Retrospective cohort study including patients with confirmed MPE who underwent definitive pleural interventions [talc poudrage by medical thoracoscopy (MT), talc slurry following chest tube drainage (CTD), or IPC placement] at a tertiary hospital between 2012 and 2022. Results: Two hundred fifty-four out of 783 MPE patients (32.4%) received definitive pleural treatment modalities—MT in 106 (41.7%), CTD in 98 (38.6%), and IPC in 50 (19.7%) patients. The overall relapse rate was 52.8%, with a median time from definitive treatment to effusion relapse of 29 days, significantly different between modalities ( P P P P P <0.001). Conclusion: This study suggests the impact of definitive pleural interventions goes beyond the palliation of symptoms, with successful pleurodesis remaining a significant predictor of improved survival regardless of performance status and systemic cancer treatments.
- 19 June 2026
- Published by Wolters Kluwer Health in Journal of Bronchology & Interventional Pulmonology
- Vol. 33 (3)
Open AccessDefinitive Pleural Interventions and Survival in Malignant Pleural Effusion
Background: Malignant pleural effusions (MPE) are associated with poor prognosis. Guidelines prioritize palliation of symptoms, recommending thoracentesis, pleurodesis or indwelling pleural catheters (IPC) based on predicted survival and patient preference. However, prognosis estimation in MPE is often inaccurate, and recent studies suggest MPE is not a bystander in the broader context of oncologic disease. Methods: Retrospective cohort study including patients with confirmed MPE who underwent definitive pleural interventions [talc poudrage by medical thoracoscopy (MT), talc slurry following chest tube drainage (CTD), or IPC placement] at a tertiary hospital between 2012 and 2022. Results: Two hundred fifty-four out of 783 MPE patients (32.4%) received definitive pleural treatment modalities—MT in 106 (41.7%), CTD in 98 (38.6%), and IPC in 50 (19.7%) patients. The overall relapse rate was 52.8%, with a median time from definitive treatment to effusion relapse of 29 days, significantly different between modalities ( P P P P P <0.001). Conclusion: This study suggests the impact of definitive pleural interventions goes beyond the palliation of symptoms, with successful pleurodesis remaining a significant predictor of improved survival regardless of performance status and systemic cancer treatments.
- Open Access
- 3 June 2025
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 51 (3) , e20250022
Out with the old – advancements and shortcomings of the updated 9th edition of the Tumor, Node, Metastasis (TNM) classification system for lung cancer
Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS). Methods: This retrospective cohort study included patients diagnosed with lung cancer between 2018 and 2021, who were staged according to both TNM-8 and TNM-9 criteria. The staging classifications were analyzed and compared in relation to OS. Results: Among a total of 914 patients, 42 were re-staged using TNM-9. Of the 382 patients classified as stage IVB, 55.9% were reclassified as M1c2. Despite an absolute increase in mean OS for patients re-staged from IIB to IIA and from IIIA to IIB, the observed differences were not statistically significant. Median OS differed significantly both within stage IVB and between patients with M1c2 disease and other stage IV subgroups. Multi-organ metastatic disease was an independent predictor of poorer OS, regardless of age, sex, performance status, and oncologic treatment. Conclusions: TNM-9 improves prognostic accuracy in lung cancer. Although patients with multiple extrathoracic metastases involving different organ systems are not yet independently staged from IVB, they demonstrated significantly poorer OS compared to other advanced-stage patients.
- 3 June 2025
- Published by Sociedade Brasileira de Pneumologia e Tisiologia in Jornal Brasileiro de Pneumologia
- Vol. 51 (3) , e20250022
Open AccessOut with the old – advancements and shortcomings of the updated 9th edition of the Tumor, Node, Metastasis (TNM) classification system for lung cancer
Objectives: The 9th edition of the Tumor, Node, Metastasis (TNM-9) lung cancer classification is set to replace the 8th edition (TNM-8) starting in 2025. Key updates include the splitting of the mediastinal nodal category N2 into single- and multiple-station involvement, as well as the classification of multiple extrathoracic metastatic lesions as involving a single organ system (M1c1) or multiple organ systems (M1c2). This study aimed to assess how the TNM-9 revisions affect the final staging of lung cancer patients and how these changes correlate with overall survival (OS). Methods: This retrospective cohort study included patients diagnosed with lung cancer between 2018 and 2021, who were staged according to both TNM-8 and TNM-9 criteria. The staging classifications were analyzed and compared in relation to OS. Results: Among a total of 914 patients, 42 were re-staged using TNM-9. Of the 382 patients classified as stage IVB, 55.9% were reclassified as M1c2. Despite an absolute increase in mean OS for patients re-staged from IIB to IIA and from IIIA to IIB, the observed differences were not statistically significant. Median OS differed significantly both within stage IVB and between patients with M1c2 disease and other stage IV subgroups. Multi-organ metastatic disease was an independent predictor of poorer OS, regardless of age, sex, performance status, and oncologic treatment. Conclusions: TNM-9 improves prognostic accuracy in lung cancer. Although patients with multiple extrathoracic metastases involving different organ systems are not yet independently staged from IVB, they demonstrated significantly poorer OS compared to other advanced-stage patients.
- Open Access
- 24 February 2025
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 96 (2)
Prospective assessment of venous thromboembolism in lung cancer patients using a standardized screening protocol
Venous thromboembolism (VTE) is highly prevalent in cancer patients. While its actual incidence remains disparate among studies, specific subpopulations, such as lung cancer patients, might be at an increased risk. We aimed to assess the impact of a screening protocol in determining both the incidence and risk factors for VTE and evaluate the usefulness of predictive biomarkers and risk stratification tools in lung cancer patients. For this purpose, we designed a prospective cohort study including all consecutive, newly diagnosed lung cancer patients between October 2023 and April 2024 in a tertiary center and assessed each patient using a standardized screening protocol. VTE screening included baseline and 3-month reassessment of coagulation tests, D-dimer levels, and imaging (duplex ultrasound of the lower limbs for deep vein thrombosis screening and contrast-enhanced thoracic computed tomography for pulmonary embolism screening). A total of 102 patients were included, of which 16 (15.7%) were diagnosed with VTE. VTE was more frequent in males (p=0.031), patients with COPD (p=0.004), and patients with metastatic disease (p=0.038), particularly those under immunotherapy (p=0.026). Patients with VTE presented a D-dimer concentration more than three times higher at baseline and fivefold the levels observed in non-VTE patients at 3 months (p=0.002). Paired with Khorana scores, D-dimer concentration 4.5 mg/L at 3 months improved the predictive capacity of this VTE risk assessment tool in patients under active treatment. Active VTE screening yielded a significant increase in diagnosis, suggesting the incidence of this complication in newly diagnosed lung cancer patients is underestimated. Risk assessment tools can be enhanced by the addition of D-dimer-based parameters.
- 24 February 2025
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 96 (2)
Open AccessProspective assessment of venous thromboembolism in lung cancer patients using a standardized screening protocol
Venous thromboembolism (VTE) is highly prevalent in cancer patients. While its actual incidence remains disparate among studies, specific subpopulations, such as lung cancer patients, might be at an increased risk. We aimed to assess the impact of a screening protocol in determining both the incidence and risk factors for VTE and evaluate the usefulness of predictive biomarkers and risk stratification tools in lung cancer patients. For this purpose, we designed a prospective cohort study including all consecutive, newly diagnosed lung cancer patients between October 2023 and April 2024 in a tertiary center and assessed each patient using a standardized screening protocol. VTE screening included baseline and 3-month reassessment of coagulation tests, D-dimer levels, and imaging (duplex ultrasound of the lower limbs for deep vein thrombosis screening and contrast-enhanced thoracic computed tomography for pulmonary embolism screening). A total of 102 patients were included, of which 16 (15.7%) were diagnosed with VTE. VTE was more frequent in males (p=0.031), patients with COPD (p=0.004), and patients with metastatic disease (p=0.038), particularly those under immunotherapy (p=0.026). Patients with VTE presented a D-dimer concentration more than three times higher at baseline and fivefold the levels observed in non-VTE patients at 3 months (p=0.002). Paired with Khorana scores, D-dimer concentration 4.5 mg/L at 3 months improved the predictive capacity of this VTE risk assessment tool in patients under active treatment. Active VTE screening yielded a significant increase in diagnosis, suggesting the incidence of this complication in newly diagnosed lung cancer patients is underestimated. Risk assessment tools can be enhanced by the addition of D-dimer-based parameters.
- Open Access
- 24 February 2025
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 96 (2)
Real-world data on home high-flow nasal cannula oxygen therapy in end-stage respiratory disease
High-flow nasal oxygen therapy (HFNOT) is a cornerstone treatment modality in severe acute hypoxemic respiratory failure, with benefits in improving oxygen deficit while normalizing breathing rate and having an effect on airway humidification. These physiological effects indicate a potential benefit in end-stage chronic respiratory failure. We aimed to assess the clinical impact of home HFNOT in reducing both exacerbation rates and overall disease burden in end-stage chronic respiratory disease. We designed a retrospective study including patients followed in the pulmonology department of a tertiary center who started home HFNOT until June 2023. Pre- and post-home HFNOT exacerbations and hospital admissions were registered, and each patient served as their own control for the statistical analysis. In total, 36 patients were included in the study: 24 patients (66.7%) with interstitial lung disease and 12 (33.3%) with obstructive lung disease. Overall, the median titrated fraction of inspired oxygen was significantly lower in obstructive patients; no significant differences were found between groups regarding titrated airflow. Obstructive patients had a significantly higher number of pre-treatment exacerbations and hospital stays. Both clinical subgroups presented fewer median overall post-treatment exacerbations and hospital admissions vs. pre-treatment start. Although mortality was high, home treatment was well tolerated by most patients, with only one patient interrupting high-flow therapy due to intolerance. Home HFNOT proved to be an overall feasible treatment strategy for patients with end-stage respiratory disease. Obstructive lung disease patients benefited the most from the treatment, possibly due to hypercapnia correction.
- 24 February 2025
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 96 (2)
Open AccessReal-world data on home high-flow nasal cannula oxygen therapy in end-stage respiratory disease
High-flow nasal oxygen therapy (HFNOT) is a cornerstone treatment modality in severe acute hypoxemic respiratory failure, with benefits in improving oxygen deficit while normalizing breathing rate and having an effect on airway humidification. These physiological effects indicate a potential benefit in end-stage chronic respiratory failure. We aimed to assess the clinical impact of home HFNOT in reducing both exacerbation rates and overall disease burden in end-stage chronic respiratory disease. We designed a retrospective study including patients followed in the pulmonology department of a tertiary center who started home HFNOT until June 2023. Pre- and post-home HFNOT exacerbations and hospital admissions were registered, and each patient served as their own control for the statistical analysis. In total, 36 patients were included in the study: 24 patients (66.7%) with interstitial lung disease and 12 (33.3%) with obstructive lung disease. Overall, the median titrated fraction of inspired oxygen was significantly lower in obstructive patients; no significant differences were found between groups regarding titrated airflow. Obstructive patients had a significantly higher number of pre-treatment exacerbations and hospital stays. Both clinical subgroups presented fewer median overall post-treatment exacerbations and hospital admissions vs. pre-treatment start. Although mortality was high, home treatment was well tolerated by most patients, with only one patient interrupting high-flow therapy due to intolerance. Home HFNOT proved to be an overall feasible treatment strategy for patients with end-stage respiratory disease. Obstructive lung disease patients benefited the most from the treatment, possibly due to hypercapnia correction.
- 31 December 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 237, 107925
Clinical impact of pre-determined guideline selection for the diagnosis of fibrotic hypersensitivity pneumonitis
- 31 December 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 237, 107925
Clinical impact of pre-determined guideline selection for the diagnosis of fibrotic hypersensitivity pneumonitis
- Open Access
- 30 November 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (6) , 555-562
Predictors of lung entrapment in malignant pleural effusion
Malignant pleural effusion (MPE) is a common complication in advanced stages of malignancy and is associated with poor prognosis. Non-expandable lung (NEL) often occurs and its presence influences the MPE approach. Our main objective was to assess risk factors for malignant NEL. Patients diagnosed with pathologically confirmed MPE between January 2012 and December 2018 in our institution were retrospectively analyzed. Demographic and clinical data of patients were reviewed and compared according to the presence or absence of NEL. A univariate and multivariate binary logistic regression analysis were used to determine predictors of the development of NEL. Of 365 patients included, 68 (18.6%) had NEL. After multivariate analysis, we found that loculated MPE (OR 8.63, 95%CI 4.30-17.33, p<0.001), complete hemithorax opacification (OR 2.81, 95%CI 1.17-6.76, p<0.021), lung cancer (OR 2.09, 95%CI 1.01-4.31, p=0.047) and higher effusion-serum LDH ratio (OR 1.09, 95%CI 1.00-1.17, p=0.039) were independent predictors of malignant NEL. There were no significant differences compared with expandable lung group regarding time from primary malignancy diagnosis to MPE diagnosis (3.0, IQR 0.0-75.8 vs 2.0, IQR 0.0-75.5 weeks, p=0.942) or MPE symptoms onset to MPE diagnosis (4.0, IQR 1.0-9.0 vs 3.0, IQR 1.0-9.0 weeks, p=0.497). Patients with NEL had a higher number of therapeutic pleural drainages (3.0, IQR 2.0-6.0 vs 2.0, IQR 1.0-3.0; p<0.001) and longer hospital stay (32.5, IQR 15.5-46.3 vs 21.0, IQR 11.0-36.0, p=0.007), measured in hospitalization days until the end of life, than patients with expandable lung. The rate of recurrence of pleural effusion was not significantly different between groups (p=0.291). Overall survival (OS) was 3.0 (95%CI, 2.3-3.7) months, regardless of lung expandability (p=0.923). Loculated MPE, complete hemithorax opacification, lung cancer and a higher effusion-serum LDH ratio were found to be independent predictors for NEL. These patients underwent thoracocenteses more frequently and had longer hospitalization days, although without significant impact in the OS.
- 30 November 2024
- Published by Taylor & Francis in Pulmonology
- Vol. 30 (6) , 555-562
Open AccessPredictors of lung entrapment in malignant pleural effusion
Malignant pleural effusion (MPE) is a common complication in advanced stages of malignancy and is associated with poor prognosis. Non-expandable lung (NEL) often occurs and its presence influences the MPE approach. Our main objective was to assess risk factors for malignant NEL. Patients diagnosed with pathologically confirmed MPE between January 2012 and December 2018 in our institution were retrospectively analyzed. Demographic and clinical data of patients were reviewed and compared according to the presence or absence of NEL. A univariate and multivariate binary logistic regression analysis were used to determine predictors of the development of NEL. Of 365 patients included, 68 (18.6%) had NEL. After multivariate analysis, we found that loculated MPE (OR 8.63, 95%CI 4.30-17.33, p<0.001), complete hemithorax opacification (OR 2.81, 95%CI 1.17-6.76, p<0.021), lung cancer (OR 2.09, 95%CI 1.01-4.31, p=0.047) and higher effusion-serum LDH ratio (OR 1.09, 95%CI 1.00-1.17, p=0.039) were independent predictors of malignant NEL. There were no significant differences compared with expandable lung group regarding time from primary malignancy diagnosis to MPE diagnosis (3.0, IQR 0.0-75.8 vs 2.0, IQR 0.0-75.5 weeks, p=0.942) or MPE symptoms onset to MPE diagnosis (4.0, IQR 1.0-9.0 vs 3.0, IQR 1.0-9.0 weeks, p=0.497). Patients with NEL had a higher number of therapeutic pleural drainages (3.0, IQR 2.0-6.0 vs 2.0, IQR 1.0-3.0; p<0.001) and longer hospital stay (32.5, IQR 15.5-46.3 vs 21.0, IQR 11.0-36.0, p=0.007), measured in hospitalization days until the end of life, than patients with expandable lung. The rate of recurrence of pleural effusion was not significantly different between groups (p=0.291). Overall survival (OS) was 3.0 (95%CI, 2.3-3.7) months, regardless of lung expandability (p=0.923). Loculated MPE, complete hemithorax opacification, lung cancer and a higher effusion-serum LDH ratio were found to be independent predictors for NEL. These patients underwent thoracocenteses more frequently and had longer hospitalization days, although without significant impact in the OS.
- 15 July 2024
- Published by Elsevier in Sleep Medicine
- Vol. 121, 258-265
The role of obstructive sleep apnea and nocturnal hypoxia as predictors of mortality in cancer patients
- 15 July 2024
- Published by Elsevier in Sleep Medicine
- Vol. 121, 258-265
The role of obstructive sleep apnea and nocturnal hypoxia as predictors of mortality in cancer patients
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA2919
Transbronchial lung cryobiopsy for the diagnosis of Fibrotic Hypersensitivity Pneumonitis
Introduction: Fibrotic Hypersensitivity Pneumonitis (fHP) is often a diagnostic challenge. Clinical and radiological features do not always ensure a high confidence level diagnosis in multidisciplinary discussion (MDD), frequently resulting in lung biopsy. ObjectiveS: To assess the role of transbronchial lung cryobiopsy (TBLC) in the diagnosis of fHP. Methods: Retrospective study including patients submitted to TBLC diagnosed with fHP between 2014-2022 in our center. Results: Of 500 TBLC performed, fHP was diagnosed in 170 patients, 55,3% male, mean age 65,82±8,26 years. Most were former/active smokers (51,2%). fHP was clinically and/or radiologically suspected before TBLC in MDD in most patients (78,8%); the majority (85,3%) reported some form of environmental exposure. High-resolution computed tomography showed a UIP-like pattern in 54,7% of cases. Most patients had no functional impairment on either spirometry (mean FVC 87,9±14,7%) nor plethysmography (mean TLC 83,1±17,1%), but presented reduced diffusion capacity (mean DLCO 56,3±14,7%). Bronchoalveolar lavage lymphocytosis was absent in two-thirds (median lymphocyte proportion 14%). The median number of samples per patient was 4 (1;7), with a mean length of 5.5mm. Two lobes were biopsied in 45,3% of patients. The most frequent complication was pneumothorax (31,7%); 23,5% of patients required chest-tube drainage. The most frequent histopathological finding was airway-centered fibrosis with peribronchiolar metaplasia (86,5%). Only 5 patients proceeded with surgical biopsy after cryobiopsy and subsequent MDD. Conclusion: TBLC proved to be a safe procedure with high yield, increasing the level of confidence for fHP in most cases presented in MDD.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA2919
Transbronchial lung cryobiopsy for the diagnosis of Fibrotic Hypersensitivity Pneumonitis
Introduction: Fibrotic Hypersensitivity Pneumonitis (fHP) is often a diagnostic challenge. Clinical and radiological features do not always ensure a high confidence level diagnosis in multidisciplinary discussion (MDD), frequently resulting in lung biopsy. ObjectiveS: To assess the role of transbronchial lung cryobiopsy (TBLC) in the diagnosis of fHP. Methods: Retrospective study including patients submitted to TBLC diagnosed with fHP between 2014-2022 in our center. Results: Of 500 TBLC performed, fHP was diagnosed in 170 patients, 55,3% male, mean age 65,82±8,26 years. Most were former/active smokers (51,2%). fHP was clinically and/or radiologically suspected before TBLC in MDD in most patients (78,8%); the majority (85,3%) reported some form of environmental exposure. High-resolution computed tomography showed a UIP-like pattern in 54,7% of cases. Most patients had no functional impairment on either spirometry (mean FVC 87,9±14,7%) nor plethysmography (mean TLC 83,1±17,1%), but presented reduced diffusion capacity (mean DLCO 56,3±14,7%). Bronchoalveolar lavage lymphocytosis was absent in two-thirds (median lymphocyte proportion 14%). The median number of samples per patient was 4 (1;7), with a mean length of 5.5mm. Two lobes were biopsied in 45,3% of patients. The most frequent complication was pneumothorax (31,7%); 23,5% of patients required chest-tube drainage. The most frequent histopathological finding was airway-centered fibrosis with peribronchiolar metaplasia (86,5%). Only 5 patients proceeded with surgical biopsy after cryobiopsy and subsequent MDD. Conclusion: TBLC proved to be a safe procedure with high yield, increasing the level of confidence for fHP in most cases presented in MDD.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA5257
Sex-related sleeping differences in non-Obstructive Sleep Apnea patients
Introduction: Evidence suggests biological sex-related differences in sleeping patterns possibly due to hormonal effects in sleep. ObjectiveS: To assess potential sleeping pattern differences between male and female patients. Methods: Retrospective study including patients submitted to polysomnography between January-December 2022 without Obstructive Sleep Apnea (OSA) diagnosis. Results: 119 patients were included, 65,5% female, with a mean age of 48,5±14,1 years. The most frequent clinical suspicion was OSA (n=49), followed by hypersomnia (n=26), parasomnia (n=22) and insomnia (n=20); females were more prevalent in all clinical suspicion groups except OSA (p<0.001). Median pre-test Epworth Sleeping Scale (ESS) was 10 (0;22); reported median ESS was significantly higher for females (11 vs 7; p=0.032). Median total sleeping time was 386 minutes (min) (13,5;556), with median sleep efficiency of 83,4% (2,6;98); no statistically significant sex-related differences were found. Likewise, there were no differences in N1, N2, N3 and REM sleep proportions when adjusted to age and medication. Females showed higher median REM sleep latency (140,5 min vs 98,8 min; p=0.009) and fewer sleep cycles (3 vs 4; p=0.011). Median oxygen saturation (SpO2) was lower in males (94,9% vs 96%; p=0.003), who presented higher cumulative time with SpO2 below 90% (0,1% vs 0%; p=0.023). Most patients (n=83) were diagnosed with some form of sleep disturbance. Biological sex significantly predicted REM latency independently of age, antidepressant intake and underlying sleep disturbance (β=37.6, p=0.033). Conclusion: Our sample showed significant sex-related differences in the clinical pre-test setting and sleep parameters in patients without OSA.
- 9 September 2023
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 62 (suppl 67) , PA5257
Sex-related sleeping differences in non-Obstructive Sleep Apnea patients
Introduction: Evidence suggests biological sex-related differences in sleeping patterns possibly due to hormonal effects in sleep. ObjectiveS: To assess potential sleeping pattern differences between male and female patients. Methods: Retrospective study including patients submitted to polysomnography between January-December 2022 without Obstructive Sleep Apnea (OSA) diagnosis. Results: 119 patients were included, 65,5% female, with a mean age of 48,5±14,1 years. The most frequent clinical suspicion was OSA (n=49), followed by hypersomnia (n=26), parasomnia (n=22) and insomnia (n=20); females were more prevalent in all clinical suspicion groups except OSA (p<0.001). Median pre-test Epworth Sleeping Scale (ESS) was 10 (0;22); reported median ESS was significantly higher for females (11 vs 7; p=0.032). Median total sleeping time was 386 minutes (min) (13,5;556), with median sleep efficiency of 83,4% (2,6;98); no statistically significant sex-related differences were found. Likewise, there were no differences in N1, N2, N3 and REM sleep proportions when adjusted to age and medication. Females showed higher median REM sleep latency (140,5 min vs 98,8 min; p=0.009) and fewer sleep cycles (3 vs 4; p=0.011). Median oxygen saturation (SpO2) was lower in males (94,9% vs 96%; p=0.003), who presented higher cumulative time with SpO2 below 90% (0,1% vs 0%; p=0.023). Most patients (n=83) were diagnosed with some form of sleep disturbance. Biological sex significantly predicted REM latency independently of age, antidepressant intake and underlying sleep disturbance (β=37.6, p=0.033). Conclusion: Our sample showed significant sex-related differences in the clinical pre-test setting and sleep parameters in patients without OSA.